When leukemia comes back or doesn't respond to treatment, a stem cell transplant can be a last hope. But the powerful, whole-body radiation used to prepare the body for the transplant can cause serious, lasting damage to the heart, lungs, and other organs. Doctors are now asking if they can use a more precise, targeted form of radiation—called intensity-modulated radiation therapy, or IMRT—to focus the dose on the bone marrow while better shielding healthy tissues.
This trial enrolled 51 patients with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). The goal of the first phase was to find the highest dose of this targeted radiation that patients could tolerate when given alongside two chemotherapy drugs, before receiving a donor's stem cells. The second phase aimed to get an early look at whether this approach might help patients survive longer without their cancer returning.
It's crucial to understand this is just a record of the trial's plan. No results on side effects, survival, or the best dose have been reported yet. This is the earliest stage of research, designed to answer basic questions about safety and feasibility. The work is being led by the City of Hope Medical Center, and while the idea of a gentler preparation for transplant is compelling, we are years away from knowing if it truly works.